Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5421441 | 1.00 | HPGD (0.31) | HPGDDGAT1GAA | |
| SCHEMBL2785917 | 0.98 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL569888 | 0.94 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL2064367 | 0.78 | HPGD (0.33) | HPGDDGAT1GAA | |
| SCHEMBL6504809 | 0.77 | CHRM2 (0.31) | — | |
| SCHEMBL3247299 | 0.77 | — | — | |
| SCHEMBL5568399 | 0.77 | HPGD (0.32) | HPGDDGAT1GAA | |
| SCHEMBL6608329 | 0.77 | HPGD (0.32) | HPGDDGAT1GAA | |
| SCHEMBL6580066 | 0.76 | LMNA (0.34) | — | |
| SCHEMBL14896297 | 0.74 | DGAT1 (0.32) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0936912-A4 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 1999-10-13 | — | — | EP | claimed |
| EP-0936912-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-25 | — | — | EP | claimed |
| WO-1998005336-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-12 | — | — | WO | claimed |
| US-20240109912-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BY) | 2024-04-04 | — | — | US | disclosed |
| CN-110452235-B | Fluorine-containing isoxazole compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-106132956-B | Heterocyclic compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2019-12-10 | — | — | CN | disclosed |
| WO-2019214656-A1 | FLUORINE-CONTAINING ISOXAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 (CN) | 2019-11-14 | — | — | WO | disclosed |
| EP-3551628-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-6166033-A | 2-carbonylthiazole derivatives and use of the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| US-5998438-A | SEROTONIN RECEPTOR ANTAGONIST; HEADACHE THERAPY | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1999-12-07 | — | — | US | disclosed |
| EP-0940401-A1 | 2-CARBONYLTHIAZOLE DERIVATIVES AND USE OF THE SAME | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5885999-A | TREATMENT OR PREVENTION OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA | MERCK SHARP & DOHME LTD. (GB) | 1999-03-23 | — | — | US | disclosed |
| US-5852049-A | Aromatic ethers derived from indoles which are useful as medicaments | PIERRE FABRE MEDICAMENT (FR) | 1998-12-22 | — | — | US | disclosed |
| US-5734059-A | Production intermediate and process for producing pyridine derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| EP-0787724-A1 | NOVEL INTERMEDIATE FOR PRODUCTION AND PROCESS FOR PRODUCING PYRIDINE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | HPGD 1103/4885DGAT1 2148/4885GAA 2279/4885 |
| US-20240109912-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CDK2, CCNK | HPGD 964/4885DGAT1 3192/4885GAA 1497/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | HPGD 1103/4885DGAT1 2148/4885GAA 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.